Factors influencing the inhibition of protein kinases

References

• Liao JJL. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:410–424.
   Google Scholar
• Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007;13:2751–2765.
   PubMed Web of Science ®Google Scholar
• Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008;51:7921–7932.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358–364.
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12:622–633.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39.
   PubMed Web of Science ®Google Scholar
• Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 2009;52:4981–5004.
   PubMed Web of Science ®Google Scholar
• Chène P, Hau JC, Blechschmidt A, Fontana P, Bohn J, Zimmermann C et al. Study of the selectivity of insulin-like growth factor-1 receptor (IGF1R) inhibitors. Open Enzyme Inh J 2010;3:27–37.
   Google Scholar
• Erdmann D, Zimmermann C, Fontana P, Hau JC, De Pover A, Chène P. Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system. J Biomol Tech 2010;21:9–17.
   Google Scholar
• Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006;11:607–615.
   PubMed Web of Science ®Google Scholar
• Bell IM, Stirdivant SM, Ahern J, Culberson JC, Darke PL, Dinsmore CJ et al. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. Biochemistry 2005;44:9430–9440.
   PubMedGoogle Scholar
• Hekmat-Nejad M, Cai T, Swinney DC. Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4. Biochemistry 2010;49:1495–1506.
   Google Scholar
• Saylor P, Wang C, Hirai TJ, Adams JA. A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps. Biochemistry 1998;37:12624–12630.
   PubMedGoogle Scholar
• Chène P. The new challenges of biochemistry in identifying the next generation of protein kinase inhibitors. Drug Discov Today 2008;13:522–529.
   Google Scholar
• Adams JA. Kinetic and catalytic mechanisms of protein kinases. Chem Rev 2001;101:2271–2290.
   PubMed Web of Science ®Google Scholar
• Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001;8:1058–1063.
   PubMedGoogle Scholar
• Li W, Favelyukis S, Yang J, Zeng Y, Yu J, Gangjee A et al. Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds. Biochem Pharmacol 2004;68:145–154.
   Google Scholar
• Wang Y, Malkowski M, Hailey J, Turek-Etienne T, Tripodi T, Pachter JA. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats. J Exp Ther Oncol 2004;4:111–119.
   Google Scholar
• García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231–239.
   PubMed Web of Science ®Google Scholar
• Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji QS et al. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. Embo J 2008;27:1985–1994.
   PubMed Web of Science ®Google Scholar
• McCarthy JT, Kumar R. Divalent Cation Metabolism: Magnesium. Blackwell Publishing, Ames, IA, 1999.
   Google Scholar
• McDermott M. The intracellular concentration of free magnesium in extensor digitorum longus muscles of the rat. Exp Physiol 1990;75:763–769.
   Google Scholar
• Adams JA, Taylor SS. Divalent metal ions influence catalysis and active-site accessibility in the cAMP-dependent protein kinase. Protein Sci 1993;2:2177–2186.
   Google Scholar
• Cook PF, Neville ME Jr, Vrana KE, Hartl FT, Roskoski R Jr. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry 1982;21:5794–5799.
   PubMedGoogle Scholar
• Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R et al. Activation loop phosphorylation modulates Bruton’s tyrosine kinase (Btk) kinase domain activity. Biochemistry 2009;48:2021–2032.
   Google Scholar
• Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, Ashcroft FM. A novel method for measurement of submembrane ATP concentration. J Biol Chem 2000;275:30046–30049.
   PubMed Web of Science ®Google Scholar
• Kennedy HJ, Pouli AE, Ainscow EK, Jouaville LS, Rizzuto R, Rutter GA. Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. Potential role for strategically located mitochondria. J Biol Chem 1999;274:13281–13291.
   PubMedGoogle Scholar
• Wang RH, Tao L, Trumbore MW, Berger SL. Turnover of the acyl phosphates of human and murine prothymosin alpha in vivo. J Biol Chem 1997;272:26405–26412.
   PubMedGoogle Scholar
• Yang J, Copeland RA, Lai Z. Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J Biomol Screen 2009;14:111–120.
   Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099–3108.
   PubMed Web of Science ®Google Scholar
• Copeland RA. Evaluation of enzyme inhibitors in drug discovery. Wiley Interscience, Hoboken, NJ, 2005.
   Google Scholar
• Yagi YI, Abe K, Ikebukuro K, Sode K. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Biochemistry 2009;48:10255–10266.
   Google Scholar
• Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA et al. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry 2008;47:8367–8377.
   Google Scholar
• Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G, Phonephaly S et al. Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 2009;48:9823–9830.
   PubMed Web of Science ®Google Scholar
• Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6:2158–2167.
   PubMed Web of Science ®Google Scholar